Evidence map›Paper›PMID 24667559›Full record

Trial reportPloS one2014

Lipoprotein metabolism indicators improve cardiovascular risk prediction.

Daniël B van Schalkwijk, Albert A de Graaf, Evgeni Tsivtsivadze, Laurence D Parnell, Bianca J C van der Werff-van der Vat, Ben van Ommen, Jan van der Greef, José M Ordovás

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Daniël B van SchalkwijkDepartment of Microbiology and Systems Biology, TNO, Zeist, The Netherlands; Amsterdam University College, Amsterdam, The Netherlands.
Albert A de GraafDepartment of Risk Analysis for Products in Development, TNO, Zeist, The Netherlands.
Evgeni TsivtsivadzeDepartment of Microbiology and Systems Biology, TNO, Zeist, The Netherlands.
Laurence D ParnellThe Nutrition and Genomics Laboratory, JM-USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts, United States of America.
Bianca J C van der Werff-van der VatDepartment of Risk Analysis for Products in Development, TNO, Zeist, The Netherlands.
Ben van OmmenDepartment of Microbiology and Systems Biology, TNO, Zeist, The Netherlands.
Jan van der GreefDepartment of Microbiology and Systems Biology, TNO, Zeist, The Netherlands; Sino-Dutch Centre for Preventive and Personalized Medicine, Leiden Amsterdam Centre for Drug Research, Analytical Sciences Division, Leiden, The Netherlands.
José M OrdovásThe Nutrition and Genomics Laboratory, JM-USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts, United States of America.
Tufts University · USAmsterdam University College · NLCentre for Human Drug Research · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCardiovascular disease risk increases when lipoprotein metabolism is dysfunctional. We have developed a computational model able to derive indicators of lipoprotein production, lipolysis, and uptake processes from a single lipoprotein profile measurement. This is the first study to investigate whether lipoprotein metabolism indicators can improve cardiovascular risk prediction and therapy management. METHODS AND

resultsWe calculated lipoprotein metabolism indicators for 1981 subjects (145 cases, 1836 controls) from the Framingham Heart Study offspring cohort in which NMR lipoprotein profiles were measured. We applied a statistical learning algorithm using a support vector machine to select conventional risk factors and lipoprotein metabolism indicators that contributed to predicting risk for general cardiovascular disease. Risk prediction was quantified by the change in the Area-Under-the-ROC-Curve (ΔAUC) and by risk reclassification (Net Reclassification Improvement (NRI) and Integrated Discrimination Improvement (IDI)). Two VLDL lipoprotein metabolism indicators (VLDLE and VLDLH) improved cardiovascular risk prediction. We added these indicators to a multivariate model with the best performing conventional risk markers. Our method significantly improved both CVD prediction and risk reclassification.

conclusionsTwo calculated VLDL metabolism indicators significantly improved cardiovascular risk prediction. These indicators may help to reduce prescription of unnecessary cholesterol-lowering medication, reducing costs and possible side-effects. For clinical application, further validation is required.

Indexed as

LipolysisModels, BiologicalSupport Vector MachineAdultCardiovascular DiseasesFemaleHumansLipoproteins, VLDLMaleMiddle AgedPredictive Value of TestsRisk FactorsLipoproteins, VLDL

Identifiers

PMID24667559
PMCPMC3965475
OpenAlexW2147151014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.